Uppsala (Sweden) and Brasschaat (Belgium), May 25th 2020 - Uppsala Therapeutics and LFSCNC today announced that they have entered into a strategic collaboration agreement to further develop Uppsala’s unique technologies based on RNAi drugs and systems for delivery through the blood brain barrier. The collaboration will leverage Uppsala Therapeutics’ deep R&D expertise with LFSCNC‘s development capabilities in order to further advance Uppsala Therapeutics’ technologies towards